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PP-091 Telbivudine results in undetectable viremia
and improved liver function in a patient with
HBsAg-positive decompensated cirrhosis:
a case report
V. Messina1 *. 1UOC Malattie Infettive, AORN S. Anna e
S. Sebastiano di Caserta, Italy
Introduction: We report here the safety and efﬁcacy of
telbivudine in a patient with chronic hepatitis B and
decompensated cirrhosis.
Case description: In 2000, a 72-year-old man naı¨ve for
interferon and nucleos(t)ide analog therapy was HBsAg
positive and hepatitis B e antigen (HBeAg) negative,
with undetectable serum hepatitis B virus (HBV) DNA and
normal alanine aminotransferase (ALT) levels and with no
evidence of liver cirrhosis. In 2005, he had a diagnosis
of adenocarcinoma of the colon and underwent resection
and chemotherapy. In 2008 he was found HBsAg negative
and received FOLFIRI plus bevacizumab and subsequently
prednisone 25mg with tapering for 15 days because of a low
platelet count. In March 2009, the patient was HBsAg posi-
tive, HBe antibody positive, hepatitis delta virus/hepatitis C
virus negative, and had an HBVDNA level of 3.31×105 IU/mL
and an ALT level 8× the upper limit of normal (ULN).
Ultrasonography revealed evidence of cirrhosis and portal
hypertension with a Child Turcotte Pugh (CTP) score of 14
and a model for end-stage liver disease (MELD) score of 24.
In April 2009, telbivudine 600mg/day was initiated.
Serum HBVDNA became undetectable (<12 IU/mL) within
2 months and ALT 1.5×ULN. At 6 months of follow-up,
HBVDNA remained undetectable, his ALT level was 0.6×ULN,
and his total and conjugated bilirubin levels were 2.3 and
0.94mg/dL, respectively. Ultrasonography showed no evi-
dence of ascites and an improvement in liver status with a
reduction in CTP and MELD scores (7 and 13, respectively).
Telbivudine resulted in a rapid suppression of HBVDNA levels
and a marked improvement of an extremely severe clinical
condition. These ﬁndings suggest that telbivudine may be of
great beneﬁt even in patients with decompensated HBsAg-
positive liver cirrhosis.
PP-092 Clinical and epidemiological analysis of
384 patients diagnosed with acute hepatitis B
B.X. Chang1 *. 1Diagnosis and Therapy Center of
Non-Infectious Disease, 302 Hospital, China
Objective: To investigate the clinical and epidemiological
characteristics of acute hepatitis B (AHB) in recent years.
Methods: To analyze the clinical data of 384 patients of AHB
by using the software SPSS 13.0.
Results: This result indicated that the susceptible
population of AHB is the patients with the age changing
from 18 to 45. The main route of transmission remained
unknown. The main nationality was Han. The morbidity of
male was higher than that of female. The rate of recovery
and improvement was 98.9%.The incidence of liver failure
is 0.5%.Six months after onset, HBsAg in 97.1% cases and
HBVDNA in 98.5% cases changed into negative.
Conclusion: The age of morbidity and the route of
transmission have changed greatly. The rate of recovery
and improvement was higher. Only few of the AHB patients
converted to the chronic HB and severe hepatitis.
PP-093 The study of efﬁcacy of lamivudine in patients
with severe acute hepatitis B
J.-W. Yu1 *, L.-J. Sun1, Y.-H. Zhao1. 1Department of
Infectious Diseases, Second Afﬁliated Hospital, Harbin
Medical University, China
The aim of this study was to evaluate the efﬁcacy of
lamivudine in patients with severe acute hepatitis B.
Methods: Eighty patients with severe acute hepatitis B were
randomly divided into lamivudine and the control group.
The inﬂuential factors on the mortality were studied by Cox
proportional hazards model.
Results: The improvement in serum TBiL, INR and HBVDNA
levels of lamivudine group was signiﬁcantly greater than
that of control group. The mortality (7.5%, 3/40) of
lamivudine group was signiﬁcantly lower than that (25.0%,
10/40) of control group (P = 0.034). In multivariate Cox
proportional hazards analyses, age (P = 0.043), ratio of
total to direct bilirubin (P = 0.009), treatment method
(P = 0.006) and the decline of HBVDNA load during therapy
(P = 0.017) were independent predictors of mortality. The
HBsAg seroconversion rates (62.5%, 25/40) and HBeAg
seroconversion rates (63.6%, 21/33) of lamivudine group
were signiﬁcantly lower than those (85.0%, 34/40), (87.5%,
28/32) of control group (P = 0.022, 0.026).
Conclusions: Early treatment with lamivudine leads to
a greater decrease in HBVDNA level, better clinical
improvement and mortality improvement in patients with
severe acute hepatitis B, but with a lower seroconversion
rate. A rapid decline of HBVDNA load is a good predictor for
the treatment outcome.
PP-094 Inﬂuential factors of prognosis in lamivudine
treatment for patients with acute-on-chronic
hepatitis B liver failure
L.-J. Sun1, J.-W. Yu1 *, P. Kang1. 1Department of Infectious
Diseases, Second Afﬁliated Hospital, Harbin Medical
University, China
In this study, the efﬁcacy of lamivudine was investigated
in patients with ACLF. The effects of HBVDNA load and
its related factors on the prognosis were also further
explored.
Methods: 130 patients receiving lamivudine were selected
into the lamivudine treatment group with another 130
without lamivudine treatment studied as control. The
inﬂuential factors on the mortality were studied by Cox
proportional hazards model.
Results: The cumulative survival rates of patients in
lamivudine group were higher than those of the control
group (c2 = 9.50, P = 0.0021). The mortality of patients with
high virus load group (71/95, 74.7%) was higher than that of
those with low virus load group (15/29, 51.7%) (c2 = 5.536,
P = 0.019). In Cox proportional hazards model, for patients
with MELD score 20 30, treatment method (P = 0.002),
pretreatment HBVDNA load (P = 0.007) and decline of
HBVDNA load during therapy (P = 0.003) were independent
predictors; for those with MELD score above 30, MELD score
(P = 0.008) was the only independent predictor.
Conclusions: Lamivudine can signiﬁcantly decrease the
3-month mortality of patients with MELD score 20 30, and a
low pre-treatment viral load and rapid decline of HBVDNA
load are good predictors for the outcome of the treatment.
PP-095 Analysis of the efﬁcacy of treatment with
peginterferon-a-2a and ribavirin in patients
coinfected with hepatitis B virus and
hepatitis C virus
J.-W. Yu1 *, L.-J. Sun1. 1Department of Infectious Diseases,
Second Afﬁliated Hospital, Harbin Medical University,
China
Objective: To study efﬁcacy of combination therapy with
peginterferon a-2a and ribavirin in these patients.
Methods: The virological response rates of patients treated
with peginterferon a-2a and ribavirin between the HBV and
HCV coinfection group and the HCV monoinfection group
were compared.
